Two new studies presented at the IgNS 2024 National Conference, in Washington, D.C., offer insight into treatment options for immune globulin (IG) therapy.
Protection Against SARS-CoV-2
In the second study (poster 106), researchers determined that plasma-derived IG infusions for treating PI provide some antibody protection against SARS-CoV-2.
“During the pandemic, we got a lot of questions about the antibody levels in our products,” said Kim Clark, PharmD, MBA, IgCP,